Pou Monica, Saval Nuria, Vera Manel, Saurina Anna, Solé Manel, Cervantes Francisco, Botey Albert
Nephrology Department, Hospital Clínic, Barcelona, Spain.
Leuk Lymphoma. 2003 Jul;44(7):1239-41. doi: 10.1080/1042819031000079140.
A 58-year-old woman with chronic myeloid leukemia (CML), and previous intolerance to interferon was treated with the BCR-ABL tyrosine kinase protein inhibitor imatinib mesylate. Coincidentally, with the start of treatment, the patient developed acute renal failure, with acute tubular necrosis being observed on histopathology. Imatinib was stopped and three hemodialysis sessions were performed, which was followed by a progressive improvement of the renal function and normalization of the urine output. One year later the patient still has mild chronic renal failure and remains in chronic phase of CML on hydroxyurea treatment.
一名58岁的慢性髓性白血病（CML）女性患者，既往对干扰素不耐受，接受了BCR-ABL酪氨酸激酶蛋白抑制剂甲磺酸伊马替尼治疗。巧合的是，治疗开始时，患者出现急性肾衰竭，组织病理学观察到急性肾小管坏死。停用伊马替尼并进行了三次血液透析，随后肾功能逐渐改善，尿量恢复正常。一年后，患者仍有轻度慢性肾衰竭，在接受羟基脲治疗的情况下仍处于CML慢性期。
